Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epsilon HealthcareASX:EPN -3.45% Days Sales Outstanding is 38.68 as of Jun. 2026, which is 63% below its 10-year median of 104.40. The stock has 4 warning signs investors should review. Among 947 Drug Manufacturers companies, Epsilon Healthcare ranks better than 88.07% on this metric.
The historical rank and industry rank for Epsilon Healthcare's Days Sales Outstanding or its related term are showing as below:
ASX:EPN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.14 Med: 104.4 Max: 136.21
Current: 34.14
During the past 10 years, Epsilon Healthcare's highest Days Sales Outstanding was 136.21. The lowest was 34.14. And the median was 104.40.
ASX:EPN's Days Sales Outstanding is ranked better than 88.07% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs ASX:EPN: 34.14
Epsilon Healthcare's Days Sales Outstanding
declined
from Jun. 2025 (68.22) to Jun. 2026 (38.68).
Epsilon Healthcare (ASX:EPN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Epsilon Healthcare Days Sales Outstanding Related Terms
Epsilon Healthcare Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Epsilon Healthcare's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Epsilon Healthcare's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epsilon Healthcare Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Epsilon Healthcare's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Epsilon Healthcare's Days Sales Outstanding falls into.
Epsilon Healthcare Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epsilon Healthcare (ASX:EPN) has a Days Sales Outstanding of 38.68 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Epsilon Healthcare and its competitors. This is 63% below median its historical median of 104.40. Over the past decade, Epsilon Healthcare's Days Sales Outstanding has ranged from 34.14 to 136.21. According to the industry distribution chart, Epsilon Healthcare ranks #113 out of 947 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is Epsilon Healthcare's Days Sales Outstanding too high?
Epsilon Healthcare's current Days Sales Outstanding of 38.68 is 63% below median its 10-year median of 104.40. Over the past 10 years, this metric has ranged from a low of 34.14 to a high of 136.21. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. Epsilon Healthcare's value of 38.68 is 46.3% below this industry median. Based on the distribution chart, Epsilon Healthcare ranks #113 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Epsilon Healthcare's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Epsilon Healthcare ranks #113 out of 947 companies for Days Sales Outstanding. This places Epsilon Healthcare in the top 12% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.98. Epsilon Healthcare's value of 38.68 is 46.3% below this benchmark. Historically, Epsilon Healthcare's own Days Sales Outstanding has ranged from 34.14 to 136.21 over the past decade. While the company's 10-year median is 104.40 vs. the industry median of 71.98, Epsilon Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epsilon Healthcare's current Days Sales Outstanding of 38.68 is 46.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Epsilon Healthcare and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epsilon Healthcare's current Days Sales Outstanding is 38.68, which is 63% below median its own 10-year median of 104.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epsilon Healthcare stock overvalued right now?
Epsilon Healthcare (ASX:EPN) has a current Days Sales Outstanding of 38.68. The current Days Sales Outstanding is 38.68, which is 63% below median its 10-year median of 104.40 and 46.3% below the Drug Manufacturers industry median of 71.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Epsilon Healthcare (ASX:EPN), the current Days Sales Outstanding is 38.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EPN has been successfully added to your 
